



## Pathogenesis and Counteracting Strategies of Hepatocellular Carcinoma, Cholangiocarcinoma and Urothelial Carcinoma

Guest Editor:

### Prof. Dr. Kung-Hao Liang

1. Department of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan
2. Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei 112, Taiwan
3. Institute of Food Safety and Health Risk Assessment, National Yang Ming Chiao Tung University, Taipei 112, Taiwan

Deadline for manuscript submissions:

**closed (15 September 2023)**

### Message from the Guest Editor

Hepatocellular carcinoma, cholangiocarcinoma and urothelial carcinoma are aggressive cancers causing morbidity, mortality and health burden worldwide. Hepatocellular carcinoma is mostly caused by chronic viral infections, while the etiology of cholangiocarcinoma and urothelial carcinoma are only partly known so far. The pathogenesis of these cancers awaits more research in order to be fully elucidated. Novel therapeutic targets and treatment strategies may arise from the investigations of the pathogenic mechanisms. Immunotherapies are becoming more and more important in treating all cancers with the advancement of knowledge about tumor-immune system interactions. The stratification of patients with respect to their distinct pathogenic mechanisms and estimated outcomes are helpful for guiding personally optimized treatments. We hereby solicit academic manuscripts regarding pathogenesis and counteracting strategies for hepatocellular carcinoma, cholangiocarcinoma and urothelial carcinoma to be considered for publication in this Special Issue of *Biomedicines*.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI